Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study ConfirmsBenzinga • 12/13/21
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression studyGlobeNewsWire • 12/13/21
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression ReductionBenzinga • 12/01/21
COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depressionGlobeNewsWire • 12/01/21
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferencesGlobeNewsWire • 11/30/21
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass PathwaysBenzinga • 11/29/21
Why We're Excited About Compass Pathways' Clinical Trial Treating PTSD With PsilocybinBenzinga • 11/22/21
Psychedelic companies say Compass study result validates industry's hope to find alternative treatments for mental healthProactive Investors • 11/18/21
COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021GlobeNewsWire • 11/09/21
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depressionGlobeNewsWire • 11/09/21
COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorderGlobeNewsWire • 11/03/21